Updated for 2026
PMHNP prescribing: CYP450 interactions, psychiatric drug safety, and adherence strategies
Safe psychiatric prescribing requires knowledge of CYP450 drug interactions, monitoring parameters for high-risk medications, serotonin syndrome recognition, and strategies to support medication adherence in patients with serious mental illness. PMHNP certification tests pharmacokinetics applied to the specific drugs used in psychiatric practice.
Educational purpose: This content is for exam preparation and professional development only. It is not intended for clinical decision-making. Always follow current guidelines, institutional policies, and scope of practice.
CYP450 interactions in psychiatric practice
CYP450 enzyme interactions are heavily tested on PMHNP certification — understanding inhibitors and inducers prevents dangerous drug interactions.
CYP2D6 (metabolises: TCAs, fluoxetine, paroxetine, many antipsychotics, codeine):
- Strong inhibitors: Fluoxetine and paroxetine (inhibit their own metabolism and other 2D6 substrates)
- Clinical consequence: Adding fluoxetine to a patient on haloperidol or risperidone → EPS/QTc risk from elevated antipsychotic levels
- Codeine → morphine conversion requires 2D6; poor metabolisers get no analgesia; ultrarapid metabolisers risk opioid toxicity
CYP3A4 (most drugs are substrates — largest enzyme family):
- Inducers: Carbamazepine, St. John's Wort, rifampin, phenytoin → lower levels of clonazepam, quetiapine, aripiprazole, lurasidone, many other substrates
- Inhibitors: Fluconazole, ketoconazole, HIV PIs → increase levels of substrates (e.g., buspirone, benzodiazepines)
CYP1A2 (metabolises: clozapine, olanzapine, haloperidol, fluvoxamine as inhibitor):
- Cigarette smoking induces CYP1A2 → smokers need higher clozapine and olanzapine doses. When patients stop smoking (hospitalisation), levels rise → toxicity if dose not reduced
- Fluvoxamine is a strong CYP1A2 inhibitor → significantly elevates clozapine levels if used together
Serotonin syndrome — recognition, severity, and management
Serotonin syndrome results from excessive serotonergic activity — typically from drug combinations. Hunter Criteria (most widely used) require a serotonergic drug + ONE of: spontaneous clonus, inducible clonus + agitation or diaphoresis, ocular clonus + agitation or diaphoresis, tremor + hyperreflexia, or hypertonia + temperature >38°C + clonus.
High-risk drug combinations:
- MAOIs + any serotonergic drug (SSRIs, SNRIs, TCAs, meperidine, tramadol, linezolid, methylene blue) — most dangerous combination, potentially fatal
- SSRI + triptans (5-HT agonists) — moderate risk; many patients take these safely, but monitor
- SSRI + tramadol or fentanyl — additive serotonergic effect
- Linezolid (antibiotic with MAOI properties) + SSRIs — clinically significant interaction
Serotonin syndrome vs. NMS: Serotonin syndrome: rapid onset (hours), hyperreflexia and clonus (distinguishing feature), agitation, diaphoresis, GI symptoms. NMS: slower onset (days), muscle rigidity (lead-pipe), no clonus, bradykinesia, elevated CK. Treatment of serotonin syndrome: stop offending drug, cyproheptadine (5-HT2 antagonist), benzodiazepines for agitation, supportive care. Severe: ICU, intubation for hyperthermia/agitation.
Frequently asked questions
- Why do smoking patients on clozapine or olanzapine need different dosing than non-smokers?
- Cigarette smoke contains polycyclic aromatic hydrocarbons (PAHs) that are potent inducers of CYP1A2 — the primary enzyme responsible for metabolising clozapine and olanzapine. Smokers have significantly higher CYP1A2 activity, meaning clozapine and olanzapine are metabolised much faster, resulting in lower drug levels at the same dose. Clinical implication: smokers typically need 30–50% higher doses of clozapine/olanzapine to achieve the same blood levels as non-smokers. The critical prescribing safety point: when a smoking patient is admitted to an inpatient psychiatric unit and cannot smoke (smoke-free environment), their CYP1A2 activity decreases within 24–48 hours. Drug levels rise toward toxicity at their current dose. Monitor for toxicity signs (excessive sedation, confusion, low BP, seizures in clozapine) and reduce dose if smoking cessation is anticipated to be sustained.
Clinically reviewed by NurseNest Clinical Review Team · Last updated 2026-06-10 · For educational purposes only · Review policy